Key Highlights
● CVS closed at $86.15 on 9 October 2026, and the second data set's $115.76 mean target implies upside of about 34%.
● Market data shows a lower $107.24 average from 23 analysts, implying about 24.5% upside, with targets from $90 to $123.
● Market data counts 20 Buy and three Hold ratings with no Sell, while the second data set shows 18 Strong Buy, seven Buy and two Hold.
● Wells Fargo raised to $123 from $103 on 13 July, the highest named target, while HSBC holds a Hold rating with a $103 target.
CVS Health Corporation (NYSE:CVS), a member of the S&P 500, closed at $86.15 on Friday 9 October 2026. Analysts covering the healthcare group see its shares trading well below their forecasts, although the two data sets give noticeably different averages.
What Is the Latest Analyst Price Target?
The second data set shows an average target of $115.76 from 27 analysts, with a median of $115, a high of $145 and a low of $103. Against the $86.15 close, the consensus target suggests potential upside of about 34%.
Market data reports a lower average of $107.24 from 23 analysts, implying upside of about 24.5%, with a high of $123 and a low of $90. The named broker targets published from July to October average roughly $113 and run from $103 to $123, which falls between the two figures.
What Are Wall Street Analysts Saying?
Ratings are strongly positive. Market data counts 20 Buy and three Hold ratings with no Sells; the second data set shows 18 Strong Buy, seven Buy and two Hold among 27 analysts.
Recent market data entries show a series of target increases. Wells Fargo raised its target to $123 from $103 on 13 July, the highest named target. JPMorgan moved to $118 from $111 on 12 August and Truist to $118 from $108 in July. Argus lifted its target to $114, RBC to $113, and BMO Capital Markets, Piper Sandler and Bernstein each set $112 targets on 9 September. HSBC holds a Hold rating with a $103 target, and Cantor Fitzgerald reiterated a Neutral rating on 9 October.
What Could Help the Stock Reach the Price Target?
The bullish case rests on the company's recent results. Market data says the latest quarter produced earnings per share of $2.58 against $1.87 expected, with revenue of $106.1 billion, up 7.3% year on year.
If results continue to beat expectations, analysts may keep lifting forecasts. The shares sit well below the lowest named target of $103, so even modest improvements in sentiment could narrow the gap.
What Could Prevent the Stock Reaching the Target?
Market data says the shares fell about 10.7% on 5 August after the report, from $104.42 to $98.14, and they have since fallen further to $86.15. That decline, despite raised targets, suggests investors may be more cautious than analysts, and some targets may lag the market.
Health insurers and pharmacy businesses face pressure from medical costs, regulation and reimbursement changes, any of which could weaken earnings. A quantitative rating service downgraded the stock from Buy to Hold on 9 October.
What Should Investors Watch Next?
Items to watch include the next report for medical cost trends and guidance, and for any change in broker targets afterwards.
CVS Trades Below Its Lowest Named Target After a Post-Results Slide
CVS closed at $86.15 on 9 October 2026, well below the lowest named broker target of $103, with named targets from July to October averaging roughly $113 between the two data sets' $107.24 and $115.76. Ratings are strongly positive and recent entries show a series of target increases, yet the shares fell about 10.7% after the August report and have declined further despite raised targets, which suggests investors may be more cautious than analysts. Market data reports earnings per share of $2.58 against $1.87 expected and revenue of $106.1 billion.






Please wait processing your request...